HOME >> MEDICINE >> NEWS
European commission grants "orphan" status for new acute myeloid leukaemia treatment

Wyeth-Ayerst Pharmaceuticals, the pharmaceutical division of American Home Products Corporation (NYSE:AHP),announced today that the European Commission has designated Mylotarg(gemtuzumab ozogamicin)as an "orphan medicinal product." The Commission decision follows a positive opinion adopted on 13 September 2000 by the Committee on Orphan Medicinal Products (COMP) of the European Agency for the Evaluation of Medicinal Products (EMEA).

"We anticipate that Mylotarg will become an important treatment option for European patients aged 60 and over with CD33-positive relapsed acute myeloid leukaemia (AML)," says L. Patrick Gage, Ph.D., President, Wyeth-Ayerst Research. "Its mechanism of action focuses on using antibody-antigen specificity to target delivery of potent chemotherapy to myeloid leukaemic cells. This compound represents the first product from Wyeth's promising oncology pipeline."

As a designated orphan medicinal product, Mylotarg will have access to the Commission's "centralised" procedure for assessment of the marketing authorisation application. Orphan medicinal products are intended to treat patients with rare life-threatening or very serious diseases for which no satisfactory method of treatment exists or where the product will be of significant benefit.

Orphan medicinal products do not automatically qualify for approval under "exceptional circumstances," but companies that sponsor orphan products receive incentives for bringing these products to the market and to the patient. Such incentives include the possibility of protocol assistance from the EMEA and fee reductions for all types of centralised marketing authorisation evaluation activities. If approved by the EMEA, Mylotarg would be the first product available in Europe from a new class of anticancer therapy known as "antibody-targeted chemotherapy." Mylotarg utilizes a patented linker technology with a novel potent anti-tumor antibiotic, calicheamicin.

Mylotarg is being develo
'"/>

Contact: Roseann Ward
roseann.ward@ketchumcomms.co.uk
44-0-207-465-8752
Ketchum
14-Nov-2000


Page: 1 2 3

Related medicine news :

1. ESC releases the first European Guidelines on Percutaneous Coronary Interventions (PCI)
2. The European Society of Cardiology launches Women at Heart
3. Use of potentially inappropriate medications among elderly common in some European countries
4. European folic acid policies are not effective enough
5. New European cancer figures for 2004 major efforts needed against the big four killers
6. Third of European cancer patients use complementary and alternative therapies
7. A new service from the European Patent Office
8. European study highlights persistent 3 decade increase in childhood cancer incidence
9. European nations urged to ratify international treaty on tobacco control
10. Increased investment in radiotherapy will improve cure rates for European cancer patients
11. ESA looking for more European women to volunteer for WISE bed-rest study in Toulouse next year

Post Your Comments:
(Date:3/3/2015)... Burlington, VT (PRWEB) March 03, 2015 In ... world’s largest environmental networks, will kick off a new campaign, ... join the network’s businesses, nonprofits, and ambassadors in their quest ... Planet will work with several of its members and partners, ... Johnson’s All At Once network, to raise awareness for food ...
(Date:3/3/2015)... (PRWEB) March 04, 2015 The report ... on the therapeutic development for Alopecia. Alopecia is the ... the two main types of alopecia. Causes for alopecia ... Symptoms of alopecia may include male pattern hair loss, ... hair. Alopecia can be classified as focal or diffuse ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 US Air ... efficiency air purification systems, is pleased to announce that all ... brief supply interruption related to the west coast port strikes. ... just around the corner. , The port ... expected to slow fourth quarter economic growth by as much ...
(Date:3/3/2015)... NY (PRWEB) March 03, 2015 Daylight Savings ... spring. Sanjeev Kothare, MD, has tips for parents. , Parents ... March 8 at 2:00 a.m. when they set their clocks ... you wake up that day -- one hour earlier -- ... That’s why parents should start thinking about “sleep hygiene” for ...
(Date:3/3/2015)... Topical BioMedics, Inc., announces its March Pain ... on Tuesday, March 10th, 12pm – 1pm and 4pm to ... 24/7. , The Pain Management Workshops are ... March 10th workshop is “Opioid Addiction: An Over-Medicated Society.” ... represents 5% of the world’s population, yet consumers 99% of ...
Breaking Medicine News(10 mins):Health News:1% For the Planet Asks Consumers to “Know Your Source” 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 2Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 3Health News:Don’t Let Daylight Savings Disrupt Your Child’s Sleep 2Health News:Topical BioMedics Hosts March Pain Management Webinar 2Health News:Topical BioMedics Hosts March Pain Management Webinar 3Health News:Topical BioMedics Hosts March Pain Management Webinar 4Health News:Topical BioMedics Hosts March Pain Management Webinar 5
(Date:3/3/2015)... - CPhI and P-MEC China 2015 ... Shanghai, China - The 15th CPhI ... at Shanghai New International Expo Center, on 24th June, 2015. ... and was introduced to China in 2001. It has successfully ... and global pharmaceutical industry over the past 15 years. With ...
(Date:3/3/2015)... NEW YORK , March 3, 2015 /PRNewswire/ ... biopharmaceutical company advancing protein biologic therapies and oncology supportive ... 27 th Annual ROTH Capital Partners Conference which ... Ritz-Carlton, Laguna Niguel in Dana Point, California.  ... is scheduled to present a corporate update on Wednesday, ...
(Date:3/3/2015)... Mar. 03, 2015 Research and Markets ... PharmaBiotech,s new report "Cardiovascular Drug Delivery - Technologies, ... Drug delivery to the cardiovascular system is ... anatomy and physiology of the vascular system; it supplies ... Drugs can be introduced into the vascular system for ...
Breaking Medicine Technology:15th Anniversary, Be Part of Chinese Pharma Dream 215th Anniversary, Be Part of Chinese Pharma Dream 3PlasmaTech Biopharmaceuticals To Present at 27th Annual ROTH Capital Partners Conference 2Global Cardiovascular Drug Delivery Technologies, Markets and Companies 2014-2024 2Global Cardiovascular Drug Delivery Technologies, Markets and Companies 2014-2024 3
Cached News: